Audience: Prescribing Providers
Based on feedback received from prescribing providers related to notification review/preauthorization requirements for medical specialty drugs, Excellus BlueCross BlueShield will update its requirements for commercial fully insured members effective January 1, 2023.
To streamline the process and eliminate the need for providers to determine which patients have a benefit that requires notification review (post-service) versus preauthorization (pre-service) for medical specialty drugs, effective January 1, 2023, drugs included on our medical specialty drug preauthorization list will require preauthorization when administered to our commercial fully insured members.
Please check this list frequently for updates, as new drugs are added as they receive FDA approval and are available for use.
Thank you for sharing the feedback that led to this process update. We hope that you find it helpful in your day-to-day business with us.Email this article